IL17A and neoplasm: Given the apparent association of Th17 cells and IL-17A with some types of IRAEs, co-administration of IL-17A/IL17AR MAbs together with ICI-targeted MAbs may not only enhance anti-tumor immunity, but also attenuate or prevent the development of IRAEs.